Skip to main content

Discover what Emgality® can do for patients with chronic migraine1

Woman having dinner at a restaurant

For your patients with ≥15 headache days per month1

Emgality reduced mean monthly MHDs1

Emgality prevented significantly more mean monthly MHDs vs placebo1a:

  • REGAIN: 4.8 with Emgality 120 mg (N=273) vs 2.7 with placebo (N=538) (baseline mean: 19.4 vs 19.6) over Months 1 to 3 (p<0.001)

Emgality demonstrated a reduction in MHDs in the first month and every following month1

Mean Change From Baseline in Monthly MHDs1,2a

Chart showing mean change from baseline in monthly migraine headache days for REGAIN

aLS means and 95% confidence intervals are presented.1-3

bEarliest post-baseline, prespecified assessment.

No formal hypothesis testing was conducted to evaluate treatment difference in mean monthly MHD reduction at each month. However, patients treated with Emgality 120 mg showed a nominally greater reduction in number of monthly MHDs at each month compared to placebo.1,2

See study design for REGAIN.

See MHD data for episodic migraine.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

For your patients with ≥15 headache days per month1

With Emgality, a significantly greater mean percentage of patients achieved a ≥50% reduction in monthly MHDs from baseline vs placebo (p<0.001)1

≥50% Reduction of Monthly MHDs From Baseline vs Placebo Over Months 1 to 31

50% response rate data for REGAIN

cp<0.001 vs placebo.1

LS=least-square; MHD=migraine headache day.

In REGAIN, Emgality 120 mg was not significantly better than placebo for the mean percentage of patients with ≥75% or 100% reduction from baseline in the number of monthly MHDs over the 3-month treatment period.1

See study design for REGAIN.

See response rate for EVOLVE-1 and EVOLVE-2.

See data for the 12-month, open-label safety study.

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

References

  1. Emgality. Prescribing Information. Lilly USA, LLC.
  2. Data on File. Lilly USA, LLC. DOF-GZ-US-0002.
  3. Data on File. Lilly USA, LLC. DOF-GZ-US-0120.

IMPORTANT SAFETY INFORMATION

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 14SEP2022

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache